This week John Vandermosten, Zacks’ Senior Biotech Analyst, speaks with CEO of ProMIS Neurosciences, Dr. Elliot Goldstein on CEO Money. ProMIS’ ticker is PMN on the Toronto Exchange and ARFXF here in the US. ProMIS is focused on finding a cure for Alzheimer’s and other neurodegenerative diseases.
Dr Elliot Goldstein
President and CEO
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the TSX (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is the discovery and development of best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
Senior Biotechnology Analyst
Zacks Small Cap Research
Business Development Manager
Blue Moon Advisors
In today’s Private Equity Spotlight, Chase Abraham, will discuss the onboarding process for Blue Moon Advisors, and what business owners need to know and be prepared for to determine their funding readiness through the Blue Moon Process
Blue Moon Advisors provides assistance and support to owners of privately held companies in their efforts to monetize, grow, and diversify their business equity. Whether your goal is obtaining seed or start-up capital, continuing to grow your business, or diversifying your net worth by exploring liquidity options, Blue Moon Advisors has the experience and expertise to guide you through the critical thought process required to achieve the two major goals of fundraising: maximum valuation and minimal time to funding.
Dr. Ellen Turner
Dermatology Office of Dr. Ellen Turner
One in 3 Texans will develop some form of skin cancer. Across the U.S., 90 percent of non-melanoma skin cancer cases (the most common kind) are associated with UV radiation exposure from the sun. People exposed to the Texas sun need to know how to protect themselves—and be aware of every option available to them. My practice just brought a non-invasive, painless treatment for skin cancer that few people know about called Superficial Radiation Therapy (SRT) to the area. SRT uses focused, low-dose radiation to stop cancer cells from spreading, without damaging healthy surrounding tissue, and has a 95% cure rate for non-melanoma skin cancer.